SHIONOGI - Lack Drivers While Crestor Approaches Climax

September 2011 | 4 pages | ID: S3D5B3E5019EN
MP Advisors

Abstracts

We have revised down our estimates on Crestor sales as it has reached its peak and Lipitor generics will be taking away share from Nov-2011. Recently negative outcome from SATURN study suggest that efforts for differentiating Crestor from Lipitor did not work-out well and therapeutic substitution is likely to hit Crestor sales more than anticipated. Our understanding remains unchanged for – pipeline candidates and overseas business. Overall, we find R&D has potential to bring drivers in long term; however we prefer to stay sideline until we get a better clarity over it.

Contents

COMPANIES MENTIONED

SHIONOGI